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ABSTRACT: Objectives: Identifying the distributions and determinants of fluoroscopy
time for invasive coronary angiography (ICA) and percutaneous coronary intervention
(PCI). Background: ICA and PCI are significant contributors to radiation exposure from
medical imaging in the US. Fluoroscopy time is a potentially modifiable determinant of
radiation exposure for these procedures, but has not been well characterized in con-
temporary practice. Methods: We evaluated the distribution of fluoroscopy time in
patients undergoing ICA and/or PCI in the CathPCI RegistryV
R
, stratifying patients by
numerous clinical scenarios. Hierarchical models were used to determine patient, pro-
cedure, operator and hospital-level factors associated with fluoroscopy time for these
procedures. Results: Our study included a total of 3,295,348 ICA and PCI procedures
performed by 9,600 operators from January 2005 through June 2009. There was wide
variation in fluoroscopy times for these procedures with median [IQR] fluoroscopy
times of 2.6 [1.7–4.5] minutes for ICA, 6.7 [4.2–10.8] minutes for ICA in patients with
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prior coronary artery bypass grafting (CABG), 10.1 [6.0–17.4] minutes for PCI, 10.7
[7.0–16.9] minutes for PCI with ICA, and 16.0 [10.6–24.0] minutes for PCI and ICA in
patients with prior CABG. Prolonged fluoroscopy times (>30 minutes) were rare for
ICA, but occurred in 6.7% of PCIs and 14.7% of PCIs in patients with prior CABG. After
accounting for patient characteristics and procedure complexity, operator and
hospital-level factors explained nearly 20% of the variation in fluoroscopy time.
Conclusions: Fluoroscopy times vary widely during ICA and PCI with operator and
hospital-level factors contributing substantially to these differences. A better under-
standing of potentially modifiable sources of this variation will elucidate opportunities
for enhancing the radiation safety of these procedures. VC 2013 Wiley Periodicals, Inc.
Key words: RDA—radiation physics; CATH—diagnostic cardiac catheterization; PCI—
percutaneous coronary intervention
INTRODUCTION
Over one million invasive coronary angiography
(ICA) and 490,000 percutaneous coronary intervention
(PCI) procedures are performed annually in the United
States [1]. These two procedures alone account for
nearly 8% of all radiation exposure from medical imag-
ing in the general population [2–4]. In contrast to
protocol-based imaging procedures such as computed to-
mography or nuclear medicine scans, the performance
of ICA and PCI also has inherent variability in its dura-
tion, leading to wide ranges of radiation exposure for
patients undergoing the same type of procedure [5–7].
In contrast to noncardiac fluoroscopic procedures,
fluoroscopy times for ICA and PCI correlate well with
air kerma-area product (R2¼ 0.53 to 0.61) [6,8], the
preferred measure for estimating total radiation expo-
sure during such procedures [9,10]. Lack of routine use
of collimation by cardiologists during ICA and PCI is
probably a key reason for this distinction between car-
diac and noncardiac fluoroscopic procedures. As fluo-
roscopy time accounts for the majority of variation in
air kerma-area product [6,8], it serves as a practical
surrogate measure of total radiation exposure during
ICA and PCI. For these reasons and based on the
ALARA principle—which states that every reasonable
effort should be made to reduce radiation exposure
[11,12]—minimizing fluoroscopy time has long been
considered a cornerstone of improving radiation safety
in cardiac catheterization labs [13,14]. Yet, despite its
importance, no national benchmarks for ICA and PCI
fluoroscopy time, with or without adjusting for
procedure complexity, have been previously developed.
Accordingly, we used data from the CathPCI Regis-
try to describe the distribution of fluoroscopy time for
ICA and PCI in the United States. In addition to
describing overall patterns of fluoroscopy time in con-
temporary practice, we also evaluated the specific con-
tribution of operator and hospital-level factors—
including operator volume—on variation in fluoroscopy
time after accounting for patient characteristics and
procedure complexity. This last analysis was performed
to elucidate potential opportunities for further enhanc-
ing the radiation safety of these procedures.
MATERIALS AND METHODS
Data Sources
We included ICA and PCI procedures that were per-
formed between January 1, 2005 and June 30, 2009 at
facilities participating in the CathPCI Registry. Details
of the registry’s participants, cohorts, and data collec-
tion methods have been described previously [15,16].
Briefly, the CathPCI Registry is an initiative of the
American College of Cardiology Foundation and the
Society for Cardiovascular Angiography and Interven-
tions, and is composed of clinical data related to diag-
nostic ICAs and/or PCIs performed at over 1,000
hospitals in the United States. Participating hospitals
submit data pertaining to characteristics of patients,
procedure findings and complications, interventions
performed, and in-hospital outcomes for all ICA and
PCI procedures performed at their facilities.
Study Population
All ICA and PCI procedures with known fluoros-
copy time and operator were eligible for this study.
Fluoroscopy time was defined as total fluoroscopy time
recorded, during the procedure, to the nearest 0.1-mi-
nute [17]. Based on specific procedure components and
the presence of prior coronary artery bypass grafting
(CABG), procedures were categorized into five mutu-
ally exclusive groups: (1) ICA, (2) ICA in patients
with prior CABG, (3) PCI, (4) PCI and ICA, and (5)
PCI and ICA in patients with prior CABG. Procedures
with missing values for ICA indication (n¼ 101), PCI
lesion location (n¼ 341), clinical presentation
(n¼ 427), or hospital census region (n¼ 6,495) were
excluded. As only the overall fluoroscopy time for any
given procedure was available, fluoroscopy times for
combined ICA and PCI procedures with two different
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operators (n¼ 17,869) were assigned to the operator
performing the PCI. Importantly, the distribution of
fluoroscopy times for procedures with unknown opera-
tor (n¼ 1,142,130) was nearly identical to that for pro-
cedures with operator identifier recorded (Appendix)
suggesting that exclusion of procedures with unknown
operator from our study did not lead to a significant
bias in fluoroscopy time.
Patient, Procedure, Operator, and Hospital Data
Patient records included data elements on demo-
graphic characteristics (age, gender, race, and insurance
status), cardiovascular risk factors (hypertension, dys-
lipidemia, family history of premature coronary artery
disease, diabetes mellitus, end-stage renal disease), car-
diovascular disease history (prior myocardial infarction,
congestive heart failure, prior PCI, cerebrovascular dis-
ease, peripheral vascular disease), clinical presentation
(asymptomatic, atypical chest pain, stable angina,
unstable angina, non-ST-segment elevation myocardial
infarction (non-STEMI), or STEMI). Procedure-related
information for ICA without PCI included indication
(rule out of coronary artery disease, valvular heart dis-
ease, evaluation of cardiomyopathy, preoperative eval-
uation for non-cardiac surgery, congenital heart
disease, or cardiogenic shock within 24 hours prior to
procedure), concomitant procedures (right heart cathe-
terization or intra-aortic balloon pump insertion), arte-
rial access site (femoral, radial or brachial), and
presence and location (native coronary arteries versus
bypass grafts) of coronary stenosis of 50%. For PCI,
lesion location and characteristics (complexity, previ-
ously treated lesion, bifurcation lesion), complications
(coronary dissection, perforation, no reflow phenom-
enon), and use of specific intracoronary devices (athe-
rectomy, thrombectomy, or extraction catheter, laser,
or embolic protection device) were also included. Sig-
nificant coronary dissection was defined as the appear-
ance of contrast materials outside the expected luminal
dimensions of the target vessel and extending longitu-
dinally >5 mm beyond the length of the lesion [18].
Operators were identified based on their Unique Physi-
cian Identification Number (UPIN) and/or National
Provider Identifier (NPI). Annual operator volume was
calculated by dividing the total number of procedures
performed by an operator in the study cohort by the
number of quarters in which they performed at least
one procedure and multiplying this value by four.
Operators who performed at least one PCI in the Cath-
PCI Registry during the study period were categorized
as interventional cardiologists. Hospital information
included data elements on teaching status, number of
beds, ownership (government, university, or commu-
nity/private), and US Census region.
Statistical Analysis
Our primary outcome was fluoroscopy time. Fluo-
roscopy times are presented as medians with inter-
quartile ranges (IQRs) given their skewed
distribution. Other continuous variables are summar-
ized as mean with standard deviation, and categorical
variables are displayed as frequencies and percen-
tages. Hierarchical multivariable regression was used
to examine the association between fluoroscopy time
and the above-mentioned patient, procedure, operator,
and hospital factors after accounting for the potential
effects of clustering of patients within operators and
hospitals [19]. A two-level hierarchical model was
used, with patient and procedure factors included in
level 1, and operator and hospital factors in level 2.
Variables included in the hierarchical models con-
sisted of the data elements listed above as well as the
year of admission to adjust for potential secular tem-
poral trends in fluoroscopy time. Given concern
about the accuracy of very high and low operator
volumes, we performed a sensitivity analysis by
repeating the hierarchical models after excluding pro-
cedures performed by operators with annual volume
of <50 or >2,000 procedures per year (n¼ 218,101).
To assess the potential influence of complicated pro-
cedures on our estimates, we also performed a sepa-
rate analysis by repeating the multivariable analyses
after excluding procedures in which major complica-
tions occurred within the catheterization laboratory,
including coronary dissection, coronary perforation,
acute coronary vessel closure, or no reflow phenom-
enon.
Finally, in order to determine the proportion of the
overall variation in fluoroscopy time that was related
to operator- and hospital-level factors (i.e., level-2 fac-
tors in the hierarchical models) we used the intraclass
correlation coefficients. In addition to the above analy-
ses, we used fractional polynomial regression to further
assess the relationship between fluoroscopy time and
operator volume. This approach has the benefit of
introducing the possibility of non-linear associations
between these two variables without imposing con-
straints using artificially constructed categories. This
relationship was evaluated separately for diagnostic
ICA (without PCI) and PCI (with or without ICA).
Because of concern about the accuracy of very high or
low annual volume estimates, operators with annual
volume of the <50 or >2,000 procedures were
excluded from this analysis to minimize the impact of
these outliers. The above listed patient, procedure,
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n % n %
Female 703,640 46.4 74,705 29.2
Age
Under 35 23,478 1.5 334 0.1
35 to <55 426,473 28.1 28,838 11.3
55 to <75 779,988 51.4 146,315 57.3
75 or over 287,991 19.0 79,944 31.3
Body mass index (kg/m2), mean (sd) 30.5 7.3 29.7 6.1
Race
White 1,220,849 80.4 221,897 86.9
Black 141,896 9.3 11,920 4.7
Other 155,185 10.2 21,614 8.5
Comorbidities
Hypertension 1,053,205 69.4 205,347 80.4
Dyslipidemia 922,456 60.8 206,783 81.0
Prior myocardial infarction 219,660 14.5 105,701 41.4
Congestive heart failure 156,579 10.3 53,142 20.8
Family history of premature CAD 395,474 26.1 69,009 27.0
Prior PCI 303,068 20.0 106,051 41.5
End-stage renal disease 282,74 1.9 6,244 2.4
Cerebrovascular disease 138,174 9.1 43,064 16.9
Peripheral vascular disease 133,329 8.8 50,160 19.6
Chronic lung disease 263,013 17.3 49,792 19.5
Diabetes mellitus 426,841 28.1 104,044 40.7
Commercial insurance 470,851 31.0 50,706 19.9
Clinical presentation
No symptoms 381,455 25.1 57,215 22.4
Atypical chest pain 353,262 23.3 35,455 13.9
Stable angina 237,111 15.6 46,368 18.2
Unstable angina 401,359 26.4 90,295 35.4
Non-ST-segment elevation MI 115,621 7.6 23,021 9.0
ST-segment elevation MI 29,122 1.9 3,077 1.2
Indication
Rule out CAD 1,430,005 94.2 238,772 93.5
Valvular heart disease 138,253 9.1 25,750 10.1
Evaluation of cardiomyopathy 407,452 26.8 110,681 43.3
Pre-operative evaluation for non-cardiac surgery 53,128 3.5 8,168 3.2
Congenital heart disease 4,805 0.3 320 0.1
Cardiogenic shock within 24 hours 13,660 0.9 2,325 0.9
Arterial access site
Femoral 1,488,066 98.0 252,328 98.8
Brachial 7,538 0.5 1,824 0.7
Radial 22,326 1.5 1,279 0.5
Intraaortic balloon pump inserted 21,864 1.4 1,992 0.8
Concomitant right heart catheterization 205,457 13.5 29,713 11.6
Coronary artery stenosis present
Native coronary vessels 519,639 34.2 244,526 95.7
Bypass grafts n/a n/a 99,733 39.0
Operator volume, mean (sd) 325 385 338 360
Operator subspecialty (interventional) 1,320,128 87.0 226,400 88.6
Teaching hospital 767,367 50.6 130,581 51.1
Hospital size >250 beds 1,208,384 79.6 205,710 80.5
Census region
Northeast 252,195 16.6 40,464 15.8
South 638,205 42.0 109,765 43.0
Midwest 430,514 28.4 74,380 29.1
West 197,016 13.0 30,822 12.1
Ownership
Government 19,689 1.3 3,615 1.4
Private/community 1,340,446 88.3 225,614 88.3
University 157,795 10.4 26,202 10.3
Year of procedure
2005 203,492 13.4 35,297 13.8
2006 281,245 18.5 47,853 18.7
2007 360,301 23.7 60,843 23.8
2008 432,796 28.5 72,228 28.3
2009 240,096 15.8 39,210 15.4
CABG, coronary artery bypass graft; CAD, coronary artery disease; MI, myocardial infarction.
TABLE II. Characteristics of Patients Undergoing Percutaneous Coronary Intervention (PCI)
PCI PCI and ICA
PCI and ICA
(prior CABG)
(n¼ 318,779) (n¼ 988,719) (n¼ 214,489)
n % n % n %
Female 108,630 34.1 342,001 34.6 56,716 26.4
Age
Under 35 1,124 0.4 6,255 0.6 206 0.1
35 to <55 58,568 18.4 251,721 25.5 24,767 11.5
55 to <75 176,941 55.5 526,823 53.3 125,641 58.6
75 or over 82,146 25.8 203,920 20.6 63,875 29.8
Body mass index (kg/m2), mean (sd) 29.9 6.3 29.8 6.4 29.6 5.9
Race
White 272,215 85.4 825,790 83.5 187,029 87.2
Black 20,777 6.5 65,476 6.6 9,783 4.6
Other 25,787 8.1 97,453 9.9 17,677 8.2
Comorbidities
Hypertension 261,642 82.1 739,809 74.8 187,145 87.3
Dyslipidemia 253,627 79.6 715,885 72.4 189,167 88.2
Prior myocardial infarction 95,437 29.9 217,493 22.0 101,298 47.2
Congestive heart failure 41,504 13.0 78,320 7.9 41,220 19.2
Family history of premature CAD 77,133 24.2 252,542 25.5 57,256 26.7
Prior PCI 125,073 39.2 322,018 32.6 114,869 53.6
End-stage renal disease 6,607 2.1 15,583 1.6 5,187 2.4
Cerebrovascular disease 42,372 13.3 92,517 9.4 38,558 18.0
Peripheral vascular disease 45,411 14.2 91,053 9.2 44,732 20.9
Chronic lung disease 57,719 18.1 151,799 15.4 39,107 18.2
Diabetes mellitus 116,346 36.5 299,150 30.3 94,142 43.9
Commercial insurance 86,197 27.0 314,768 31.8 47,376 22.1
Clinical presentation
No symptoms 59,849 18.8 111,398 11.3 24,933 11.6
Atypical chest pain 21,905 6.9 74,379 7.5 14,512 6.8
Stable angina 65,188 20.4 134,238 13.6 35,637 16.6
Unstable angina 112,758 35.4 305,277 30.9 93,901 43.8
Non-ST-segment elevation MI 39,775 12.5 170,434 17.2 33,949 15.8
ST-segment elevation MI 19,304 6.1 192,993 19.5 11,557 5.4
Cardiogenic shock within 24 hours 4,022 1.3 26,625 2.7 3,333 1.6
Arterial access site
Femoral 311,907 97.8 968,916 98.0 212,138 98.9
Brachial 1,486 0.5 3,273 0.3 1,040 0.5
Radial 5,386 1.7 16,530 1.7 1,311 0.6
Intraaortic balloon pump inserted 5,486 1.7 30,758 3.1 3,683 1.7
Number of lesions intervened
upon: mean (SD)
1.5 0.8 1.4 0.7 1.4 0.7
Concomitant right heart
catheterization
1,958 0.6 44,379 4.5 11,107 5.2
PCI lesion characteristics
Previously treated lesion 29,267 9.2 95,433 9.7 35,050 16.3
Complex lesion (class C) 135,593 42.5 409,495 41.4 100,115 46.7
Bifurcation lesion 47,381 14.9 123,243 12.5 21,434 10.0
PCI lesion location
Native coronary vessel 293,707 92.1 988,719 100.0 132,587 61.8
Bypass graft- artery 18,699 5.9 0 0.0 65,292 30.4
Bypass graft-vein 1,532 0.5 0 0.0 4,433 2.1
Multiple locations (any
combination of above locations)
4,841 1.5 0 0.0 12,177 5.7
Use of intracoronary devices
Atherectomy, thrombectomy
catheter, or laser
14,097 4.4 61,042 6.2 11,218 5.2
Embolic protection device 6,796 2.1 1,275 0.1 15,855 7.4
Procedural complications
Significant dissection 10,510 3.3 29,278 3.0 5,127 2.4
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operator, and hospital characteristics were included in
these models.
Two-tailed P< 0.05 was considered statistically sig-
nificant for all tests. All analyses were performed using
SAS version 9.2 (SAS Institute, Cary, NC) and Stata
version 11 (StataCorp LP, College Station, TX).
RESULTS
We examined 1,773,361 diagnostic ICAs (without
PCI) and 1,521,987 PCIs (with or without ICA) per-
formed in 2,768,434 patients by 9,600 operators at 942
hospitals during the study period. The mean age of
patients was 63.5 (612.5) years, 1,285,692 (39.0%)
were female, and 535,912 (16.3%) had had prior
CABG. Tables I and II display baseline characteristics
of the study population stratified by procedure cate-
gory.
Distribution of Fluoroscopy Times
Median fluoroscopy times for each procedure cate-
gory are listed in Table III. There was wide variation
in fluoroscopy times for all procedure categories (Fig.
1). The presence of coronary artery bypass grafts was
associated with increases of 4.1 and 5.3 minutes in me-
dian fluoroscopy times for ICA and ICA with PCI,
respectively. ICAs performed for evaluation of patients
with valvular heart disease and congenital heart disease
were associated with longer fluoroscopy times as com-
pared to other indications such as ruling out coronary
artery disease (Fig. 2—top panel). These differences in
fluoroscopy times by ICA indication were less promi-
nent in patients with prior CABG (Fig. 2—bottom
panel).
Fluoroscopy times of greater than 30 minutes were
uncommon for ICA but occurred in a sizeable minority
of patients undergoing PCI, ranging in this latter group
from 6.7% in patients without prior CABG to nearly
15% of those with prior CABG (Table III). Approxi-
mately 1.3% of PCI patients had fluoroscopy times of
more than 60 minutes, a threshold beyond which the
risk of radiation-related skin injury increases signifi-
cantly.
Multivariable Analyses
Incremental fluoroscopy times associated with
patient, operator, and hospital factors after multivari-
able adjustment are listed in Tables IV and V, sepa-
rately for ICA and PCI. For ICA, factors associated
with the largest increments in fluoroscopy time were
brachial arterial access (up to 6.0 minutes of added flu-
oroscopy time), radial arterial access (up to 3.6
minutes), congenital heart disease (3.2 minutes), con-
comitant right heart catheterization (2.7 minutes), a
university hospital setting (up to 2.6 minutes), and
presence of coronary stenosis of 50% in patients with
prior CABG (up to 1.7 minutes) (Table IV). Other fac-
tors associated with longer fluoroscopy times during
TABLE II. Continued
PCI PCI and ICA
PCI and ICA
(prior CABG)
(n¼ 318,779) (n¼ 988,719) (n¼ 214,489)
n % n % n %
Coronary perforation 1,276 0.4 3,820 0.4 995 0.5
No reflow phenomenon 3,229 1.0 13,575 1.4 3,881 1.8
Operator volume 325 363 311 391 333 402
Teaching hospital 160,423 50.3 515,930 52.2 112,766 52.6
Hospital size >250 beds 266,768 83.7 816,600 82.6 178,677 83.3
Census region
Northeast 41,626 13.1 155,807 15.8 30,218 14.1
South 154,464 48.5 382,764 38.7 89,494 41.7
Midwest 84,664 26.6 291,127 29.4 63,543 29.6
West 38,025 11.9 159,021 16.1 31,234 14.6
Ownership
Government 6,097 1.9 12,035 1.2 2,522 1.2
Private/community 278,905 87.5 871,974 88.2 187,831 87.6
University 33,777 10.6 104,710 10.6 24,136 11.3
Year of procedure
2005 49,392 15.5 129,498 13.1 27,915 13.0
2006 67,185 21.1 183,340 18.5 39,809 18.6
2007 74,771 23.5 234,064 23.7 50,486 23.5
2008 83,833 26.3 287,065 29.0 62,312 29.1
2009 43,598 13.7 154,752 15.7 33,967 15.8
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ICA included age 75 years, peripheral vascular dis-
ease, valvular heart disease, and lower operator volume
(Table IV).
For PCI, the largest increments in fluoroscopy time
were associated with significant coronary dissection or
perforation (up to a 7.7 minute increase in fluoroscopy
time), use of atherectomy, thrombectomy or extraction
catheter or laser (up to 7.1 minutes), brachial artery
access (up to 7.2 minutes), number of lesions inter-
vened upon, university hospital setting (up to 4.9
minutes), intra-aortic balloon pump insertion (up to 3.7
minutes), and radial artery access (up to 3.3 minutes)
(Table V). In addition, age 75 years, endstage renal
disease, peripheral vascular disease, concomitant right
heart catheterization, complex (class C) or bifurcation
lesions, no reflow phenomenon, lower operator volume,
and Northeast and West census regions were associated
with substantial increases in fluoroscopy time (Table
V). Intervention on every additional coronary lesion
was associated with an average increase of nearly 4
minutes in fluoroscopy time. Right heart catheterization
concomitant with any PCI procedure was, on average,
Fig. 1. Distribution of fluoroscopy times for invasive coronary angiography (ICA) and percu-
taneous coronary intervention (PCI) procedures. CABG indicates coronary artery bypass
graft.
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associated with 2.1 minutes of additional fluoroscopy
time.
Female gender was associated with modestly shorter
fluoroscopy times for both ICA and PCI, ranging from
0.3 to 1.3 fewer minutes of fluoroscopy time. Presenta-
tion with STEMI was also associated with shorter fluo-
roscopy times (up to 1.9 minutes) as compared with
other clinical presentations. After accounting for
patient, procedure, operator, and hospital factors, there
was a modest but statistically significant temporal trend
for decreasing fluoroscopy times for PCI during the
study period (decline of 1.0–1.5 minutes over the study
period). There were no significant changes in our
results after excluding procedures performed by opera-
tors with annual procedure volume of <50 or >2,000.
Similarly, exclusion of procedures in which coronary
dissection, coronary perforation, acute coronary vessel
closure, or no reflow phenomenon occurred did not
significantly alter our findings.
Overall, after accounting for differences in patient
characteristics and procedure complexity, operator and
hospital-level factors explained 17.0% and 19.0% of
the variation in fluoroscopy time for ICA and PCI,
respectively. Mean operator volume was 118 (6148)
procedures per year with 87.2% of ICAs performed by
an interventional cardiologist. After multivariable
adjustment, interventional cardiologists had lower ICA
fluoroscopy times as compared to noninterventionalists,
particularly in patients with prior CABG. Operators’
average fluoroscopy time for each of the five proce-
dure categories varied widely, indicating substantial
operator-level variation in fluoroscopy times (Fig. 3).
Operator volume was inversely associated with fluo-
roscopy time. The magnitude of this association varied
by procedure category, ranging from a reduction of
0.50 minutes in fluoroscopy time per 250 cases per-
formed per year for ICA in patients without prior
CABG to 1.49 minutes per 250 cases performed per
year for ICA with PCI in patients with prior CABG.
Fractional polynomials regression analysis confirmed a
significant operator volume–fluoroscopy time relation-
ship and also indicated that this relationship was stron-
ger for PCI as compared to ICA (Fig. 4).
DISCUSSION
In this large, contemporary national registry of
patients undergoing ICA and PCI in the United States,
we found wide variation in fluoroscopy times for these
procedures, including substantial operator and hospital-
level variation. However, we found a large proportion
(approximately 80%) of this variation was “fixed” in
Fig. 2. Distribution of fluoroscopy times for invasive coronary
angiography (ICA) stratified by clinical indication in patients
without prior CABG (top panel) and with prior CABG (bottom
panel). The boxplots denote the interquartile range and the
lower and upper whiskers display the 5th and 95th percen-
tiles, respectively. CABG indicates coronary artery bypass
graft; CAD, coronary artery disease.
TABLE III. Distribution of Fluoroscopy Time for Invasive Coronary Angiography (ICA) and Percurtaneous Coronary
Intervention (PCI)
Table 1. Distribution of fluoroscopy time for ICA and PCI procedures
ICA ICA (prior CABG) PCI PCI and ICA
PCI and ICA
(prior CABG)
Fluoroscopy time (min.), median (IQR) 2.6 (1.7–4.5) 6.7 (4.2–10.8) 10.1 (6.0–17.4) 10.7 (7.0–16.9) 16.0 (10.6–24.0)
10th percentile, 90th percentile 1.2–8.1 2.9–16.5 3.7–28.1 4.9–25.9 7.3–34.6
5th percentile, 95th percentile 1.0–11.5 2.2–21.2 2.9–37.0 3.9–33.3 5.8–43.0
1st percentile, 99th percentile 0.6–23.2 1.3–34.1 1.7–60.3 2.4–53.6 3.3–63.7
Mean physician-level fluoroscopy
time (min.), median (IQR)
4.1 (3.1–5.4) 9.0 (6.9–11.9) 13.6 (10.3–18.1) 13.3 (10.6–16.7) 18.8 (15.0–23.6)
Fluoroscopy time >30 min., no. (%) 8,044 (0.5%) 4,031 (1.6%) 27,146 (8.5%) 66,006 (6.7%) 31,462 (14.7%)
Fluoroscopy time >60 min., no. (%) 1,556 (0.1%) 351 (0.1%) 3,226 (1.0%) 6,205 (0.6%) 2,810 (1.3%)
CABG, coronary artery bypass graft; IQR, interquartile range.
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TABLE IV. Incremental ICA Fluoroscopy Time (in Minutes, with 95% CI) Associated with Listed Variables After Multivariable
Adjustment
Variable ICA ICA (prior CABG)
Female gender 0.31 (0.33 to 0.29) 0.83 (0.89 to 0.77)
Age
Under 35 0.51 (0.59 to 0.44) 2.06 (2.80 to 1.32)
35 to <55 0.83 (0.86 to 0.80) 1.82 (1.92 to 1.71)
55 to <75 0.60 (0.62 to 0.57) 0.98 (1.04 to 0.91)
75 or over Ref Ref Ref Ref
Body mass index (per kg/m2) 0.015 (0.014 to 0.016) 0.03 (0.03 to 0.04)
Race
White Ref Ref Ref Ref
Black 0.035 (0.069 to 0.001) 0.20 (0.06 to 0.33)
Other 0.06 (0.09 to 0.02) 0.07 (0.05 to 0.18)
Comorbidities
Hypertension 0.13 (0.10 to 0.15) 0.19 (0.11 to 0.27)
Dyslipidemia 0.03 (0.05 to 0.01) 0.10 (0.18 to 0.02)
Prior myocardial infarction 0.06 (0.09 to 0.03) 0.13 (0.19 to 0.07)
Congestive heart failure 0.12 (0.09 to 0.16) 0.11 (0.18 to 0.04)
Family history of premature CAD 0.07 (0.10 to 0.05) 0.02 (0.08 to 0.05)
Prior PCI 0.02 (0.04 to 0.01) 0.87 (0.93 to 0.81)
End-stage renal disease 0.01 (0.08 to 0.06) 0.51 (0.34 to 0.69)
Cerebrovascular disease 0.22 (0.18 to 0.25) 0.20 (0.12 to 0.27)
Peripheral vascular disease 0.99 (0.95 to 1.02) 0.92 (0.84 to 0.99)
Chronic lung disease 0.027 (0.002 to 0.051) 0.04 (0.03 to 0.11)
Diabetes mellitus 0.14 (0.16 to 0.12) 0.24 (0.29 to 0.18)
Commercial insurance 0.08 (0.10 to 0.06) 0.17 (0.24 to 0.10)
Clinical presentation
No symptoms Ref Ref Ref Ref
Atypical chest pain 0.28 (0.32 to 0.27) 0.43 (0.52 to 0.33)
Stable angina 0.22 (0.25 to 0.19) 0.19 (0.28 to 0.10)
Unstable angina 0.27 (0.30 to 0.24) 0.37 (0.45 to 0.29)
Non-ST-segment elevation MI 0.28 (0.32 to 0.24) 0.19 (0.30 to 0.08)
ST-segment elevation MI 0.02 (0.05 to 0.09) 0.09 (0.17 to 0.35)
Indication
Rule out CAD 0.33 (0.37 to 0.28) 0.10 (0.03 to 0.23)
Valvular heart disease 1.35 (1.32 to 1.39) 0.93 (0.83 to 1.03)
Evaluation of cardiomyopathy 0.18 (0.20 to 0.16) 0.27 (0.33 to 0.21)
Pre-op evaluation for
noncardiac surgery
0.04 (0.01 to 0.09) 0.12 (0.04 to 0.27)
Congenital heart disease 3.22 (3.06 to 3.39) 0.19 (0.57 to 0.95)
Cardiogenic shock within 24 hours 0.21 (0.12 to 0.31) 0.23 (0.53 to 0.06)
Arterial access site
Femoral Ref Ref Ref Ref
Brachial 4.69 (4.56 to 4.82) 5.98 (5.66 to 6.30)
Radial 2.74 (2.65 to 2.84) 3.59 (3.18 to 4.00)
Intraaortic balloon pump inserted 0.52 (0.44 to 0.60) 0.15 (0.17 to 0.47)
Concomitant right heart
catheterization
2.75 (2.72 to 2.78) 2.69 (2.59 to 2.79)
Coronary artery stenosis present
Native coronary vessels 0.80 (0.78 to 0.83) 1.72 (1.58 to 1.85)
Bypass grafts n/a n/a 0.80 (0.74 to 0.85)
Operator volume
(/250 procedures per year)
0.50 (0.54 to 0.41) 1.35 (1.49 to 1.22)
Operator subspecialty (interventional) 0.18 (0.27 to 0.09) 1.23 (1.46 to 1.01)
Teaching hospital 0.23 (0.17 to 0.29) 0.32 (0.17 to 0.48)
Hospital size >250 beds 0.06 (0.11 to 0.00) 0.09 (0.24 to 0.07)
Census region
Northeast Ref Ref Ref Ref
South 0.06 (0.16 to 0.04) 0.98 (1.23 to 0.73)
Midwest 0.12 (0.23 to 0.01) 0.81 (1.07 to 0.55)
West 0.01 (0.13 to 0.11) 0.47 (0.77 to 0.18)
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that it was tied directly to patient characteristics and
procedural complexity, which are largely non-
modifiable factors. This finding alone highlights the
need to consider “adjustment” of fluoroscopy time and
other quality measures of radiation safety when bench-
marking these procedures. Yet we also noted that oper-
ator and hospital-level factors, including operator
volume, had a moderate impact on fluoroscopy time,
contributing to nearly 20% of its variation even after
accounting for differences in patient characteristics and
procedure complexity.
These findings have important implications for qual-
ity improvement. First, outlining the distribution of flu-
oroscopy times for contemporary ICA and PCI
provides a basis for defining national benchmarks for
this measure. As cardiac catheterization labs increas-
ingly adopt strategies for operators and their institu-
tions to enhance the radiation safety of these
procedures, these results provide a reference basis for
gauging improvement. Second, we identified key
patient and procedure factors associated with fluoros-
copy time, which could be used to adjust such bench-
marks to account for procedure complexity. This is
important because of the strong correlation between
procedure complexity and radiation exposure for both
ICA and PCI. Finally, these findings highlight the
potential for quality improvement by noting the impor-
tant role that operator and hospital-level factors play in
determining fluoroscopy times beyond patient charac-
teristics and procedure complexity.
Our findings also have significant population health
implications given the high prevalence of these proce-
dures. For example, a modest reduction in fluoroscopy
time for ICA from the 75th percentile to the 50th per-
centile translates into a 42% reduction in actual fluo-
roscopy time. Assuming a linear relationship between
fluoroscopy time and KAP, this would lead to a pro-
portionate decrease in effective dose, e.g., from 7 mSv
to 4.1 mSv for the average ICA [20]. While such a
dose reduction is small for an individual patient
(roughly equivalent to annual US background radiation
exposure from natural sources), it would translate to
much more substantial, meaningful reductions in radia-
tion exposure at the population level [21]. Importantly,
simple technical measures such as increased use of col-
limation and reducing the dose-rate for fluoroscopy
and cine could help achieve even greater reductions in
radiation exposure from ICA and PCI. This highlights
the importance and potential impact of efforts such as
the Image Wisely campaign [22], which focuses on
enhancing radiation safety of medical imaging, includ-
ing fluoroscopic procedures, by educating health care
professionals and patients. By partnering with such
programs, the American Heart Association, American
College of Cardiology and Society for Cardiac Angiog-
raphy and Intervention could provide a much wider
platform for these educational efforts among cardiolo-
gists and other health care providers. In order to nar-
row the current knowledge gap [23,24], it is also
imperative that principles of radiation safety, including
appropriate use of cardiac imaging and dose reduction
techniques, be incorporated in cardiology fellowship
training curricula in a meaningful manner. This knowl-
edge should also be required for recertification of prac-
ticing operators.
Several key factors deserve to be highlighted given
their potential for modification. For example, we found
that operator volume was inversely associated with flu-
oroscopy time for ICA and PCI, a relationship that has
been noted for other types of fluoroscopic procedures
in prior studies [25]. This finding likely reflects the
greater efficiency of more experienced operators and is
consistent with the volume–outcomes relationship dem-
onstrated for these procedures in previous studies
[26,27]. Longer fluoroscopy times at university hospi-
tals may be related to the involvement of trainees in
procedures performed at these hospitals, which have
been shown to increase fluoroscopy time for other flu-
oroscopic procedures [25,28]. From this standpoint,
greater awareness and focus on radiation safety during
TABLE IV. Continued
Variable ICA ICA (prior CABG)
Ownership
Private/community Ref Ref Ref Ref
Government 0.29 (0.07 to 0.51) 0.05 (0.48 to 0.58)
University 1.55 (1.46 to 1.65) 2.57 (2.31 to 2.83)
Year of procedure
2005 Ref Ref Ref Ref
2006 0.02 (0.05 to 0.02) 0.04 (0.14 to 0.06)
2007 0.07 (0.10 to 0.04) 0.23 (0.32 to 0.13)
2008 0.12 (0.16 to 0.09) 0.33 (0.42 to 0.23)
2009 0.16 (0.20 to 0.13) 0.63 (0.74 to 0.52)
CABG, coronary artery bypass graft; CAD, coronary artery disease.
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TABLE V. Incremental PCI (with or without ICA) Fluoroscopy Time (in Minutes, with 95% CI) Associated with Listed Variables
After Multivariable Adjustment
Variable PCI ICA and PCI ICA and PCI (prior CABG)
Female gender 0.89 (0.97 to 0.81) 0.71 (0.75 to 0.67) 1.24 (1.36 to 1.13)
Age
Under 35 1.26 (1.89 to 0.62) 1.34 (1.58 to 1.10) 2.04 (3.59 to 0.49)
35 to <55 1.92 (2.05 to 1.79) 2.10 (2.16 to 2.04) 2.16 (2.34 to 1.98)
55 to <75 0.97 (1.06 to 0.87) 1.21 (1.27 to 1.16) 0.93 (1.05 to 0.82)
75 or over Ref Ref Ref Ref Ref Ref
Body mass index 0.012 (0.005 to 0.018) 0.024 (0.021 to 0.028) 0.03 (0.02 to 0.04)
Race
White Ref Ref Ref Ref Ref Ref
Black 0.08 (0.08 to 0.24) 0.17 (0.09 to 0.25) 0.14 (0.11 to 0.38)
Other 0.32 (0.47 to 0.16) 0.13 (0.21 to 0.06) 0.04 (0.17 to 0.24)
Comorbidities
Hypertension 0.42 (0.31 to 0.52) 0.41 (0.36 to 0.46) 0.31 (0.17 to 0.46)
Dyslipidemia 0.21 (0.11 to 0.30) 0.10 (0.05 to 0.14) 0.02 (0.18 to 0.13)
Prior myocardial infarction 0.21 (0.12 to 0.30) 0.33 (0.28 to 0.39) 0.01 (0.11 to 0.10)
Congestive heart failure 0.05 (0.07 to 0.17) 0.15 (0.07 to .22) 0.13 (0.26 to 0.00)
Family history of premature CAD 0.07 (0.16 to 0.03) 0.09 (0.14 to 0.05) 0.01 (0.12 to 0.11)
Prior PCI 0.23 (0.32 to 0.14) 0.29 (0.34 to 0.24) 0.83 (0.94 to 0.73)
End-stage renal disease 1.30 (1.03 to 1.57) 1.19 (1.04 to 1.35) 1.18 (0.86 to 1.50)
Cerebrovascular disease 0.20 (0.09 to 0.31) 0.29 (0.22 to 0.35) 0.05 (0.08 to 0.18)
Peripheral vascular disease 0.89 (0.78 to 1.00) 1.14 (1.07 to 1.21) 0.75 (0.62 to 0.87)
Chronic lung disease 0.08 (0.02 to 0.18) 0.09 (0.03 to 0.14) 0.15 (0.28 to 0.03)
Diabetes mellitus 0.09 (0.17 to 0.01) 0.10 (0.15 to 0.06) 0.16 (0.27 to 0.06)
Commercial insurance 0.12 (0.21 to 0.02) 0.13 (0.09 to 0.17) 0.27 (0.39 to 0.14)
Clinical presentation
No symptoms Ref Ref Ref Ref Ref Ref
Atypical chest pain 0.12 (0.29 to 0.06) 0.27 (0.36 to 0.18) 0.22 (0.46 to 0.02)
Stable angina 0.11 (0.01 to 0.24) 0.03 (0.11 to 0.05) 0.15 (0.04 to 0.34)
Unstable angina 0.05 (0.17 to 0.06) 0.48 (0.55 to 0.41) 0.14 (0.31 to 0.03)
Non-ST-segment elevation MI 0.31 (0.45 to 0.16) 0.56 (0.63 to 0.48) 0.11 (0.30 to 0.09)
ST-segment elevation MI 1.54 (1.73 to 1.35) 1.87 (1.95 to 1.79) 1.47 (1.73 to 1.20)
Cardiogenic shock within 24 hours 0.24 (0.59 to 0.11) 0.22 (0.09 to 0.35) 0.44 (0.86 to 0.03)
Arterial access site
Femoral Ref Ref Ref Ref Ref Ref
Brachial 4.58 (4.03 to 5.12) 5.69 (5.36 to 6.02) 7.24 (6.55 to 7.93)
Radial 1.27 (0.90 to 1.64) 3.23 (3.03 to 3.43) 3.27 (2.57 to 3.96)
Intra-aortic balloon pump inserted 3.74 (3.43 to 4.04) 2.80 (2.67 to 2.92) 3.06 (2.66 to 3.46)
Concomitant right heart catheterization na na 2.13 (2.03 to 2.22) 2.15 (1.91 to 2.38)
Number of lesions intervened upon 3.95 (3.90 to 4.00) 4.01 (3.98 to 4.04) 3.88 (3.80 to 3.96)
PCI lesion characteristics
Previously treated lesion 0.33 (0.11 to 0.55) 0.68 (0.57 to 0.79) 0.23 (0.44 to 0.02)
Complex lesion (class C) 3.81 (3.73 to 3.83) 2.91 (2.87 to 2.95) 2.81 (2.71 to 2.92)
Bifurcation lesion 1.43 (1.31 to 1.54) 1.53 (1.47 to 1.59) 1.23 (1.06 to 1.40)
PCI lesion location
Native coronary vessel Ref Ref N/A N/A Ref Ref
Bypass graft-artery 1.32 (1.52 to 1.11) 0.27 (0.39 to 0.15)
Bypass graft-vein 0.53 (0.02 to 1.08) 1.48 (1.14 to 1.82)
Multiple locations (any combination
of above locations)
0.80 (0.48 to 1.13) 0.88 (0.65 to 1.11)
Use of intracoronary devices
Atherectomy, thrombectomy
catheter, or laser
7.13 (6.94 to 7.32) 2.75 (2.66 to 2.83) 5.06 (4.83 to 5.29)
Embolic protection device 0.78 (1.08 to 0.49) 2.14 (1.61 to 2.67) 0.07 (0.28 to 0.13)
Procedural complications
Significant dissection 7.05 (6.84 to 7.27) 6.33 (6.22 to 6.44) 7.67 (7.35 to 7.99)
Coronary perforation 6.47 (5.88 to 7.07) 4.43 (4.12 to 4.73) 4.35 (3.64 to 5.06)
No reflow phenomenon 1.45 (1.07 to 1.83) 1.72 (1.56 to 1.89) 1.83 (1.45 to 2.20)
Operator volume
(/250 procedures per year)
1.04 (1.26 to 0.81) 1.17 (1.35 to 0.99) 1.49 (1.76 to 1.22)
Teaching hospital 0.22 (0.02 to 0.46) 0.42 (0.30 to 0.54) 0.62 (0.35 to 0.89)
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training may improve the use of these procedures [29].
Finally, modest regional variation in PCI fluoroscopy
times noted in our study may be related to differences
in rates of adoption of newer fluoroscopy cameras
(with options such as last image hold or cine loop that
allow reduction in fluoroscopy times), operator volume
and experience, awareness of radiation safety princi-
ples, and local efforts to reduce fluoroscopy time. It is
important to develop further understanding of operator
and hospital determinants of fluoroscopy time, as they
will provide insights into specific approaches that may
improve radiation safety.
We identified other factors associated with increased
fluoroscopy time, but the extent to which these factors
are modifiable is less clear. Nonfemoral arterial access,
particularly brachial arterial access, was associated with
significantly longer fluoroscopy times for both ICA and
PCI. As brachial arterial access is often obtained after
failed attempts to gain radial and/or femoral arterial
access, the added fluoroscopy time associated with this
approach may be a reflection of difficult arterial access
in patients with peripheral vascular disease. The pres-
ence of coronary stenosis was associated with longer
fluoroscopy times, which may be related to the addi-
tional images and views needed to accurately character-
ize lesions. Factors contributing to longer fluoroscopy
times in the elderly probably include a combination of
the above factors, i.e., more difficult access because of
increased peripheral vascular disease as well as more
coronary disease requiring additional images to define
coronary anatomy. In patients with congenital heart dis-
ease, navigation of and defining the complex anatomy
likely adds to the fluoroscopy time. The shorter fluoros-
copy times in patients presenting with STEMI may be
related to the more time-sensitive nature of these inter-
ventions where the operator’s primary goal is re-
establishing coronary flow as quickly as possible.
Finally, possible causes of the modest decrease in aver-
age fluoroscopy times over time during the study period
include improved image quality with newer cameras,
the increased availability of options such as last image
hold and loop replay, and increasing awareness of radi-
ation safety principles among operators.
Finally, several patient and procedure-related factors
that we identified as being associated with increased
fluoroscopy time are less predictable and should prob-
ably be used to place excessive radiation exposures,
when they occur, into appropriate clinical context. For
example, operators typically only utilize atherectomy,
thrombectomy, or extraction catheters or laser when
lesion complexity necessitates their use. Similarly, there
are much more pressing reasons to avoid complications
such as coronary dissection or perforation than risks
related to radiation exposure. However, understanding
TABLE V. Continued
Variable PCI ICA and PCI ICA and PCI (prior CABG)
Hospital size >250 beds 0.18 (0.45 to 0.09) 0.11 (0.23 to 0.01) 0.23 (0.06 to 0.52)
Census region
Northeast Ref Ref Ref Ref Ref Ref
South 1.21 (1.63 to 0.80) 0.75 (1.01 to 0.50) 1.52 (1.98 to 1.06)
Midwest 1.06 (1.50 to 0.61) 0.86 (1.14 to 0.58) 1.08 (1.57 to 0.59)
West 0.50 (0.01 to 0.99) 0.01 (0.29 to 0.30) 0.01 (0.52 to 0.54)
Ownership
Private/community Ref Ref Ref Ref Ref Ref
Government 0.97 (1.85 to 0.09) 0.46 (1.07 to 0.15) 0.51 (1.63 to 0.61)
University 3.64 (3.26 to 4.01) 2.95 (2.75 to 3.14) 4.88 (4.47 to 5.29)
Year of procedure
2005 Ref Ref Ref Ref Ref Ref
2006 0.23 (0.36 to 0.10) 0.33 (0.40 to 0.26) 0.14 (0.32 to 0.03)
2007 0.59 (0.72 to 0.46) 0.66 (0.73 to 0.59) 0.64 (0.82 to 0.46)
2008 0.77 (0.90 to 0.63) 0.93 (1.00 to 0.86) 0.94 (1.11 to 0.76)
2009 1.06 (1.22 to 0.91) 1.25 (1.33 to 1.17) 1.46 (1.66 to 1.26)
Fig. 3. Distribution of average physician-level fluoroscopy
times for invasive coronary angiography (ICA) and percutane-
ous coronary intervention (PCI). The boxplots denote the
interquartile ranges and the lower and upper whiskers display
the 5th and 95th percentiles, respectively. CABG indicates
coronary artery bypass graft.
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the relationship between these factors and increased flu-
oroscopy time may still be useful in these settings. Flu-
oroscopy time cannot be used as an indicator of peak
skin dose because it does not account for key determi-
nants of peak dose such as dose-rate, projection angles,
cine use, and patient size. However, in cases with pro-
longed fluoroscopy times, operators should pay even
closer attention to monitoring total air kerma at the ref-
erence point (also known as cumulative air kerma),
which indicates peak skin dose. Attention to the princi-
ples of radiation safety with fluoroscopy (Table VI) is
particularly important in such cases. In our study, fluo-
roscopy times exceeded 30 minutes in 8.1% of PCIs
and 60 minutes in 0.8% of PCIs. In cases in which the
total air kerma at the reference point exceeds 5 Gy,
early follow-up and more extensive patient education to
monitor for skin injury is appropriate [9]. Both total air
kerma at the reference point and air kerma-area product
are reported by all fluoroscopy machines manufactured
since 2006 as mandated by the Food and Drug Admin-
istration [30]. Registries such as the CathPCI Registry
should incorporate these measures in order to provide
more accurate and meaningful feedback regarding radi-
ation safety to participating hospitals.
Our study should be interpreted in the context of the
following limitations. First, because of the limitations of
our data source, we used fluoroscopy time rather than
air kerma-area product which is admittedly a more
appropriate and accurate estimate of radiation exposure
[9]. However, prior studies have shown that for ICA and
PCI, in contrast to noncardiac fluoroscopic procedures,
there is a good correlation between fluoroscopy
time and air kerma-area product (published estimates
of correlation coefficient [R]¼ 73% to 78%), and
fluoroscopy time is a modifiable and easily
understandable factor that is responsible for the majority
of its variation across these procedures [6,8,9]. Second,
we defined operator volume based on procedures
recorded in the CathPCI Registry and did not capture
procedures performed in other (non-CathPCI Registry-
participating) hospitals. As this approach is likely to
lead to underestimations of operator volume, it would
minimize the degree of associations between operator
volume and fluoroscopy time that we identified. Finally,
we excluded procedures for which key data were
missing, but these constituted a very small proportion
(<2%) of the overall procedures and their exclusion was
unlikely to create a significant bias in the study results.
CONCLUSIONS
There is wide variation in fluoroscopy times for ICA
and PCI procedures. Operator and hospital factors con-
tribute significantly to this variation and provide poten-
tial targets for improving the radiation safety of these
procedures.
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Fig. 4. Operator volume–fluoroscopy time relationship for
invasive coronary angiography (ICA) and percutaneous coro-
nary intervention (PCI).
TABLE VI. Fluoroscopic Dose-Rate Management Techniques
 Keep the patient as close as reasonably possible to the image receptor
and as far as possible from the x-ray tube.
 Use collimation to reduce the irradiated area.
 Use the lowest acceptable magnification.
 Use the lowest clinically acceptable dose-rate at all times.
 Use fluoroscopy only for real-time imaging guidance.
 Use image acquisition (Cine or DSA) only when higher-quality image
review is essential.
 Use last-image-hold or loop replay in place of live imaging whenever
practicable. In some cases, retrospectively stored fluoroscopy may
replace image acquisition.
 Minimize the number of cine series.
 Never use cine as a substitute for fluoroscopy.
 Use wedge filters when they are appropriate.
 Try to avoid steeply angulated projections (especially LAO cranial).
 Try to vary the C-arm angulation slightly, to avoid concentrating the
radiation dose at a single site on the patient‘s skin.
 Remember that for large patients, and also for steeply angulated
projections, the dose to the patient increases substantially.
 Pay attention to the patient radiation dose display in the procedure
room.
 If the patient has had previous similar procedures, try to obtain
information about the previous radiation doses to optimize subsequent
procedures.
Adapted from NCRP-168 and ICRP Draft Report for Consultation on
Patient and Staff Radiological Protection in Cardiology.
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APPENDIX
Fluoroscopy times (in minutes) of procedures in the CathPCI
Registry during the study period in which the operator ID was








Std Deviation 10.57 10.67




75% (3rd quartile) 12.0 12.0
50% (median) 6.0 5.9




0% (minimum) 0.0 0.0
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